This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Defining key tasks and accelerating the construction of new urbanization
Successful Multinational Corporations in China Series: Qualcomm China
Jun 25, 2022 02:02 PM